Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Merck’s return to ophthalmology snags first success

Merck’s $1.3 billion upfront bet on EyeBio in 2024 is starting to pay off. The New Jersey drug giant, attempting to expand its therapeutic arsenal beyond Keytruda, reported ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Read the original at endpoints.news →

More in Health & Medicine

More from Thursday 24 September →